A drug has been recently discussed in the Yale University news letter: “In 2014, King showed that tofacitinib, marketed as Xeljanz, could be used to treat alopecia areata. The new study confirms the validity of that report and builds a case for pursuing treatment of the disease with this and similar drugs.”

Some of my patients think that this will be used for standard genetic alopecia, but it will not

Read it here: ““This study demonstrates the drug is effective for treating alopecia areata,” said Dr. Brett A. King of Yale School of Medicine, who designed the study with Dr. Brittany Craiglow. In 2014, King showed that tofacitinib, marketed as Xeljanz, could be used to treat alopecia areata. The new study confirms the validity of that report and builds a case for pursuing treatment of the disease with this and similar drugs.”